Latest Heart News
Some 500,000 people in the United States have the procedure -- medically called percutaneous coronary intervention -- annually, the FDA said in a news release. Formation of a blood clot during the procedure could lead to heart attack.
As with any anti-clotting drug, life-threatening bleeding is a potential side effect, the agency noted.
In clinical trials, Kengreal was compared to the anti-clotting drug Plavix (clopidogrel) among more than 10,000 participants. Cases of serious bleeding, while still rare, were more common among users who took Kengreal than Plavix, the FDA said.
Kengreal is manufactured by The Medicines Co., based in Parsippany, N.J.
-- Scott Roberts
Copyright © 2015 HealthDay. All rights reserved.